We launch our bio-based polyolefins to reduce the medical sector's carbon footprint
Menu

16.10.2023

REPSOL Quimica, S.A.

We launch our bio-based polyolefins to reduce the medical sector's carbon footprint

Our new advanced bio-based range offers a negative carbon footprint, removing more CO2 from the atmosphere than it emits. It is a game-changing solution for the medical sector, designed to meet the industry's growing demand for eco-friendly solutions.
We unveiled our latest solution to reduce CO2 emissions and promote eco-friendliness. We offer our pioneering range of bio-based polyolefins, a first-generation range made from sustainable organic oils, and second-generation bio-based polyolefins, made from organic waste, for pharmaceutical applications. With a strong focus on eco-design, the range replaces traditional feedstock from refineries with bio-based feedstock from sustainable crops oil or the reuse of organic waste.

Our new advanced bio-based range offers a negative carbon footprint on a cradle-to-gate methodology under the ISO 14067 standard, removing more CO2 from the atmosphere than the emissions in the supply chain processes. Replacing the traditional feedstock used at our industrial sites with this new bio-based feedstock, which has previously removed CO2 from the atmosphere by photosynthesis during its plantation life cycle, improves carbon footprint to -1 tCO2/t for our first-generation polyolefins and -2,5 tCO2/t for our second-generation polyolefins. Furthermore, this bio-based range is ISCC Plus certified for traceability through mass balance. In addition, the new bio-based polyolefins meet these applications' strict cleanliness and safety requirements. These eco-friendly solutions are already available to our pharmaceutical packaging and medical device clients in the European market, meeting the European pharmacopeia standards and offering healthcare manufacturers an opportunity to reduce CO2 emissions while prioritizing product safety. While the global medical devices market is projected to grow significantly due to increasing healthcare expenditure, advancements in medical technology, and the growing demand for non-invasive medical procedures, there is an increasing commitment towards reducing its carbon footprint.

Repsol's new bio-based range of polyolefins marks a significant step in the company's commitment to decarbonization to meet its goal to become a net-zero emissions company by 2050. In addition, Repsol's bio-based range offers a unique solution for the healthcare industry to reduce its carbon footprint.

Our new bio-based range of polyolefins marks a significant step in our commitment to decarbonization to meet our goal to become a net-zero emissions company by 2050.

Exhibitor Data Sheet